Essa Pharma Stock Current Valuation
| EPIX Stock | USD 1.83 0.07 3.98% |
Valuation analysis of ESSA Pharma helps investors to measure ESSA Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to rise to -31.71 in 2024. Enterprise Value Multiple is likely to rise to -31.71 in 2024. Fundamental drivers impacting ESSA Pharma's valuation include:
Price Book 0.6304 | Enterprise Value -49.1 M | Enterprise Value Ebitda (8.09) |
Undervalued
Today
Please note that ESSA Pharma's price fluctuation is very risky at this time. Calculation of the real value of ESSA Pharma is based on 3 months time horizon. Increasing ESSA Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ESSA Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ESSA Stock. However, ESSA Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.83 | Real 6.2 | Target 19.4 | Hype 1.8 | Naive 3.39 |
The intrinsic value of ESSA Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ESSA Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ESSA Pharma helps investors to forecast how ESSA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ESSA Pharma more accurately as focusing exclusively on ESSA Pharma's fundamentals will not take into account other important factors: ESSA Pharma Company Current Valuation Analysis
ESSA Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ESSA Pharma Current Valuation | (49.12 M) |
Most of ESSA Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ESSA Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ESSA Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for ESSA Pharma is extremely important. It helps to project a fair market value of ESSA Stock properly, considering its historical fundamentals such as Current Valuation. Since ESSA Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ESSA Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ESSA Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ESSA Pharma has a Current Valuation of (49.12 Million). This is 100.34% lower than that of the Biotechnology sector and 101.06% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.3% higher than that of the company.
ESSA Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ESSA Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ESSA Pharma could also be used in its relative valuation, which is a method of valuing ESSA Pharma by comparing valuation metrics of similar companies.ESSA Pharma is currently under evaluation in current valuation category among its peers.
ESSA Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of ESSA Pharma from analyzing ESSA Pharma's financial statements. These drivers represent accounts that assess ESSA Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ESSA Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 14.4M | 28.4M | 154.9M | 80.1M | 136.2M | 61.5K | |
| Enterprise Value | 3.1M | (21.2M) | 98.6M | 23.3M | 102.6M | 60.7K |
ESSA Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (49.12 M) | ||||
| Shares Outstanding | 44.39 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 81.18 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 0.63 X | ||||
| EBITDA | (26.46 M) | ||||
| Net Income | (26.58 M) | ||||
| Cash And Equivalents | 174.6 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 80.33 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 43.43 X | ||||
| Book Value Per Share | 2.90 X | ||||
| Cash Flow From Operations | (19.78 M) | ||||
| Short Ratio | 30.53 X | ||||
| Earnings Per Share | (0.62) X | ||||
| Target Price | 13.2 | ||||
| Number Of Employees | 50 | ||||
| Beta | 1.84 | ||||
| Market Capitalization | 81.23 M | ||||
| Total Asset | 149.12 M | ||||
| Retained Earnings | (179.46 M) | ||||
| Working Capital | 145.3 M | ||||
| Current Asset | 10.02 M | ||||
| Current Liabilities | 3.63 M | ||||
| Net Asset | 149.12 M |
About ESSA Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ESSA Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ESSA Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ESSA Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.